

Docket No: 110.01270101

Serial No.: 09/937,076

DECLARATION AND POWER OF ATTORNEY

We, James B. McCarthy, William J. Mileski, Gordon A. Jamieson, Jr., Walter C. Low, Ronald J. Sawchuk, and Leo T. Furcht, declare that: (1) our respective citizenships and residence/mailing addresses are indicated below; (2) we have reviewed and understand the contents of the specification identified below, including the claims, as amended by any amendment specifically referred to herein, (3) we believe that we are the original, first, and joint inventors of the subject matter in

METHODS OF USE OF β1-INTEGRIN INHIBITORS

Filing Date: September 19, 2001

described and claimed therein and for which a patent is sought; and (4) we hereby acknowledge our duty to disclose to the United States Patent and Trademark Office all information known to us to be material to the patentability as defined in Title 37, Code of Federal Regulations, §1.56.*

We hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate listed below, or §365(a) of any PCT international application which designates at least one country other than the United States of America listed below, and have also identified below any foreign application for patent or inventor's certificate, or any PCT international application having a filing date before that of the application on the basis of which priority is claimed:


a. X no such applications have been filed.

b. ___ such applications have been filed as follows:

FOREIGN APPLICATION(S), IF ANY, CLAIMING PRIORITY UNDER 35 USC §119(a)-(d), §365(a), and/or §365(b)			
COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	DATE OF ISSUE (day, month, year)

ALL FOREIGN APPLICATIONS, IF ANY, FILED BEFORE THE PRIORITY APPLICATION(S)			
COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	DATE OF ISSUE (day, month, year)

^{*}Title 37, Code of Federal Regulations, §1.56 is reproduced on the attached page.



Page 2 of 4

Declaration and Power of Attorney

Serial No.: 09/937,076

Filing Date: September 19, 2001 (Int'l Filing Date: March 22, 2000)

Title: METHODS OF USE OF \(\beta\)I-INTEGRIN INHIBITORS

We hereby claim the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

a. ___ no such applications have been filed.

b. X such applications have been filed as follows:

PROVISIONAL APPLICATION(S), IF ANY, UNDER 35 USC §119(e)		
APPLICATION NUMBER	DATE OF FILING (day, month, year)	
60/125,634	22 March 1999	
60/167,538	24 November 1999	

We hereby claim the benefit under Title 35, United States Code, §120 of any United States applications or §365(c) of any PCT international application(s) designating the United States of America, listed below.

a. ___ no such applications have been filed.

b. \underline{X} such applications have been filed as follows:

APPLICATION NUMBER	DATE OF FILING (day, month, year)	STATUS (patented, pending, abandoned)
PCT/US00/07680	22 March 2000	Pending

Insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of Title 35, United States Code, §112, we acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

We hereby appoint Ann M. Mueting (Reg. No. 33,977), Kevin W. Raasch (Reg. No. 35,651), Mark J. Gebhardt (Reg. No. 35,518), Victoria A. Sandberg (Reg. No. 41,287), David L. Provence (Reg. No. 43,022), Matthew W. Adams (Reg. No. 43,459). Loren Albin (Reg. No. 37,763). Kathleen L. Franklin (Reg. No. 47,574), and Joseph C. Huebsch (Reg. No. 42,673) our attorneys with full powers (including the powers of appointment, substitution, and revocation) to prosecute this application and any division, continuation, continuation-in-part, reexamination or reissue thereof, and to transact all business in the Patent and Trademark Office connected therewith.

Please direct all correspondence in this case to:

Attention: Ann M. Mueting
Mueting, Raasch & Gebhardt, P.A.

P.O. Box 581415

Minneapolis, MN 55458-1415

Telephone No. (612) 305-1217

Customer Number 26813

The undersigned declare further that all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under

9



Declaration and Power of Attorney

Serial No.: 09/937,076

Residence: Mailing Address:

(If different than Residence)

Filing Date: September 19, 2001 (Int'l Filing Date: March 22, 2000) Title: METHODS OF USE OF \(\beta\)I-INTEGRIN INHIBITORS Page 3 of 4

Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Wherefore, we pray that Letters Patent be granted to us for the invention described and claimed in the specification identified above and we hereby subscribe our names to the foregoing specification and claims, Declaration, and Power of Attorney on the date indicated below.

Oce	en A. Mir	2/21/02
Name: Citizenship: Residence: Mailing Addre (If different the		Date 406, USA MN
Name: Citizenship: Residence: Mailing Addre (If different that		Date
Name Citizenship: Residence: Mailing Addre (If different that		Date O H
Name Citizenship: Residence: Mailing Addre (If different that		<u>02-21-02</u> Date
Name Citizenship: Residence: Mailing Addre (If different that		Date 112, USA M N
Name Citizenship:	Leo T. Furcht United States of America	Date

2100 West 21st Street, Minneapolis, Minnesota 55405, USA

MN

Name:

Name

Name

Name

Name

Citizenship: Residence: Mailing Address:

Citizenship:

Mailing Address:

Residence:

Citizenship:

Residence:

Mailing Address:

Citizenship: Residence:

Mailing Address:

Citizenship:

(If different than Residence)

(If different than Residence)

(If different than Residence)

(If different than Residence)

(If different than Residence

Residence: Mailing Address:

William I. Mileski United States of America

Gordon A. Jamieson, Jr. United States of America

United States of America

Walter Cl Llow

Ronald J. Sawchuk

United States of America

4220 Pindies Beach, Galveston, Texas 77554, USA

3422 Ault View Avenue, Cincinnati, Ohio 45208, USA

19845 Sweetwater Curve, Shorewood, Minnesota 55331, USA

1702 - 20th Avenue NW, New Brighton, Minnesota 55112, USA

Leo T. Furcht
United States of America
2100 West 21st Street, Minneapolis, Minnesota 55405, USA

2/20/02

Date

Date

Date

Date

Declaration and Power of Attorn	ey Page 3 of 4
Serial No.: 09/937,076	
	! (Int'l Filing Date: March 22, 2000)
Title: METHODS OF USE OF I	31-INTEGRIN INHIBITORS
	nited States Code and that such willful false statements may jeopardize the validity of
the application or any patent issui	ng thereon.
Wherefore, we pray that	at Letters Patent be granted to us for the invention described and claimed in the
	we hereby subscribe our names to the foregoing specification and claims, Declaration,
and Power of Attorney on the date	
Name: James B. McCa	arthy Date
Citizenship: United States of	f America
Residence: 2555 - 37th Ave	enue South, Minneapolis, Minnesota 55406, USA
Mailing Address:	II
(If different than Residence)	

Fax:6126246554

Feb 20 023 34 04 7 4. 02 02 2 7 6 2

Page 3 of 4

Declaration and Power of Attorney

Serial No.: 09/937,076

Filing Date: September 19, 2001 (Int'l Filing Date: March 22, 2000)

Title: METHODS OF USE OF BI-INTEGRIN INHIBITORS

United States of America

2100 West 21st Street, Minneapolis, Minnesota 55405. USA

Citizenship:


Residence: Mailing Address:


(If different than Residence)

Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Wherefore, we pray that Letters Patent be granted to us for the invention described and claimed in the specification identified above and we hereby subscribe our names to the foregoing specification and claims, Declaration, and Power of Attorney on the date indicated below.

N1	Lun II McCorthy	Date		
Name: Citizenship:	James B. McCarthy United States of America	Dute		
Residence: 2555 - 37th Avenue South, Minneapolis, Minnesota 55406, USA Mailing Address: (If different than Residence)				
Name:	William J. Mileski	Date		
Citizenship: Residence: Mailing Addre: (If different tha		20 PEBRUARY 200 7		
Name Citizenship: Residence: Mailing Addre (If different tha		Date		
Name Citizenship: Residence: Mailing Addre (If different the		Date		
Name Citizenship: Residence: Mailing Addre (If different th		Date SA		
Name	Leo T. Furcht	Date		





Page 3 of 4

Declaration and Power of Attorney

Serial No.: 09/937.076

Filing Date: September 19, 2001 (Int'l Filing Date: March 22, 2000)

Title: METHODS OF USE OF \$1-INTEGRIN INHIBITORS

Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Wherefore, we pray that Letters Patent be granted to us for the invention described and claimed in the specification identified above and we hereby subscribe our names to the foregoing specification and claims, Declaration, and Power of Attorney on the date indicated below.

Date Name: James B. McCarthy Citizenship: United States of America Residence: 2555 - 37th Avenue South, Minneapolis, Minnesota 55406, USA Mailing Address: (If different than Residence) Date William J. Mileski Name: Citizenship: United States of America Residence: 4220 Pirates Beach, Galveston, Texas 77554, USA Mailing Address: (If different than Residence) Date Name Gordon A. Jamieson, Jr. United States of America Citizenship: 3422 Ault View Avenue, Cincinnati, Ohio 45208, USA Residence: Mailing Address: (If different than Residence) Date Name Walter C. Low Citizenship: United States of America Residence: 19845 Sweetwater Curve, Shorewood, Minnesota 55331, USA Mailing Address: (If different than Residence) Name United States of America Citizenship: 1762 - 20th Avenue NW, New Brighton, Minnesota 55112, USA Residence: Mailing Address: (If different than Residence)

Name

Leo T. Furcht

Date

Citizenship:

Residence:

United States of America

2100 West 21st Street, Minneapolis, Minnesota 55405, USA

Mailing Address:

(If different than Residence) -

Page 3 of 4

Declaration and Power of Attorney

Serial No.: 09/937,076

Filing Date: September 19, 2001 (Int'l Filing Date: March 22, 2000)

Title: METHODS OF USE OF AL-INTEGRIN INHIBITORS

Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Wherefore, we gray that Letters Patent be granted to us for the invention described and claimed in the specification identified above and we hereby substribe our names to the foregoing specification and claims, Declaration, and Power of Attorney on the date indicated below.

Name:

James B. McCarthy

Date

Date

Dale

Date

Citizenship:

United States of America

Residence:

2555 - 37th Avenue South, Minneapolis, Minnesota 55406, USA

Mailing Address:

(If different than Residence)

Name:

William J. Mileski

Citizenship:

United States of America

Residence:

4220 Pirates Beach, Galveston, Texas 77554, USA

Mailing Address:

(If different than Residence)

Name

Gordon A. Jamieson, Jr.

Citizenship:

United States of America

Residence:

3422 Ault View Avenue, Cincinnati, Ohio 45208, USA

Mailing Address:

(If different than Residence)

Name

Walter C. Low

Citizenship:

United States of America

Residence:

1984S Sweetwater Curve, Shurewood, Minnesota 55331, USA

Mailing Address:

(If different than Residence)

Name

Ronald J. Sawchuk

Date

Citizenship:

United States of America

Residence:

1702 - 20th Avenue NW, New Brighton, Minnesota 55112, USA

Malling Address:

(If different than Residence)

1/2 //1

7

Name

Lyo T. Furch

Citizenship:

United States of America


Residence:

2100 West 21st Street, Minneapolis, Minnesota 55405, USA

Mailing Address:

(If different than Residence)

Page 4 of 4



Serial No.: 09/937,076

Filing Date: September 19, 2001 (Int'l Filing Date: March 22, 2000)

Title: METHODS OF USE OF \$1-INTEGRIN INHIBITORS

§ 1.56 Duty to disclose information material to patentability.

A patent by its very nature is affected with a public interest. The public interest is best served, and (a) the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is cancelled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is cancelled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:

- (1) Prior art cited in search reports of a foreign patent office in a counterpart application, and
- (2) The closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.
- (b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and
 - (1) It establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim; or
 - (2) It refutes, or is inconsistent with, a position the applicant takes in:
 - (i) Opposing an argument of unpatentability relied on by the Office, or
 - (ii) Asserting an argument of patentability.

A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.

- (c) Individuals associated with the filing or prosecution of a patent application within the meaning of this section are:
 - (1) Each inventor named in the application;
 - (2) Each attorney or agent who prepares or prosecutes the application; and
 - (3) Every other person who is substantively involved in the preparation or prosecution of the application and who is associated with the inventor, with the assignee or with anyone to whom there is an obligation to assign the application.
- (d) Individuals other than the attorney, agent or inventor may comply with this section by disclosing information to the attorney, agent, or inventor.
- (e) In any continuation-in-part application, the duty under this section includes the duty to disclose to the Office all information known to the person to be material to patentability, as defined in paragraph (b) of this section, which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.